David Krempa, Chief Business Officer, on May 22, 2026, sold 100,000 shares in Eton Pharmaceuticals (ETON) for $3,229,923. Following the Form 4 filing with the SEC, Krempa has control over a total of 25,249 common shares of the company, with 25,249 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1710340/000143774926018628/xslF345X05/rdgdoc.xml